ClinicalTrials.gg
CompletedNCT03840148CERTAIN-1Updated Jun 6, 2025Results posted

Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections

A Phase 3 interventional study of Cefepime/VNRX-5133 (taniborbactam) and Meropenem in Urinary Tract Infections and Acute Pyelonephritis, sponsored by Venatorx Pharmaceuticals, Inc.. Completed at 78 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-06.

Sponsored by Venatorx Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
661
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 26 studies in Urinary Tract Infections with a site in China — 6 open to participants now, 6 under way, none of them phase 3. Urinary Tract Infections · China.

Enrollment
2nd of 22
661 · median 150
Started
2019
with 2 others
Phase 3
7 of 26
none open now
Registered
6th of 26
by date

Among the 26 studies in Urinary Tract Infections with a site in China, this one is the 2nd largest by enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2019, is one of 7 in phase 3, and was the 6th registered.

Urinary Tract Infections

804 studies on the registry are indexed under Urinary Tract Infections; 134 are open to participants now.

Browse Urinary Tract Infections studies →

Open to participants now

6 of the 26 studies in Urinary Tract Infections with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 84 Urinary Tract Infections studies recruiting now, 50 (60%) set no upper age limit and 24 (29%) stop at 75 or younger; 16 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Urinary Tract Infections with a site in China, or all of them as a file.
02

Study summary

This study will assess the safety and efficacy of cefepime/VNRX-5133 compared with meropenem in both eradication of bacteria and in symptomatic response in patients with cUTIs.

03

Conditions studied

  • Urinary Tract Infections
  • Acute Pyelonephritis

Keywords

  • Bacterial Infections
  • Cefepime
  • Meropenem
  • Complicated Urinary Tract Infections
  • Anti-Infective Agents
  • β-Lactamase Inhibitors
  • VNRX-5133 (taniborbactam)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult male and female
  • Documented diagnosis of pyuria
  • Documented diagnosis of cUTI or Acute Pyelonephritis (AP)

Exclusion criteria

Exclusion Criteria:

  • Receipt of effective antibacterial drug therapy for cUTI for more than 24 hours during the previous 72 hours prior to randomization
  • A urine culture result is resistant to meropenem or a gram negative pathogen is not identified or more than 2 microorganisms are isolated or a confirmed fungal UTI is identified
  • Required use of nonstudy systemic bacterial therapy
  • Suspected or confirmed prostatitis or urinary tract symptoms attributable to sexually transmitted disease
  • Patients with perinephric or renal abscess
  • Patients with renal transplantation or receiving hemodialysis or peritoneal dialysis
  • Abnormal labs
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
661 participants (actual)

Study arms

  • Experimental
    Cefepime/VNRX-5133 (taniborbactam)

    Cefepime/VNRX-5133 administered q8h intravenously (IV) over a 2-hour period.

    Drug: Cefepime/VNRX-5133 (taniborbactam)

  • Active comparator
    Meropenem

    Meropenem will be administered q8h IV over 30 minutes.

    Drug: Meropenem

Interventions

  • DrugCefepime/VNRX-5133 (taniborbactam)

    Drug page: Taniborbactam

    Cefepime/VNRX-5133 administered q8h intravenously (IV) over a 2-hour period for 7 days (up to 14 days for patients with bacteremia). Patients will also receive meropenem placebo administered via IV over 30 minutes.

  • Meropenem will be administered q8h IV over 30 minutes for 7 days (up to 14 days for patients with bacteremia). Patients will also receive cefepime/VNRX-5133 placebo administered via IV over a 2-hour period.

06

What researchers measure

Primary outcomes

  1. Composite Success at Test of Cure (TOC) in the Microbiological Intent-to-treat (microITT) Population

    Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

    Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)

Secondary outcomes

  1. Microbiologic Success at Test of Cure (TOC) in the microITT Population

    Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.

    Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)

  2. Clinical Success at Test of Cure (TOC) in the microITT Population

    Symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

    Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)

  3. Composite Success at Test of Cure (TOC) in the Extended Microbiological Intent-to-treat (emicroITT) Population

    Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

    Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)

  4. Composite Success at End of Treatment (EOT) in the microITT Population

    Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

    Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)

  5. Microbiological Success at End of Treatment (EOT) in the microITT Population

    Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.

    Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)

  6. Clinical Success at End of Treatment (EOT) in the microITT Population

    Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

    Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)

  7. Composite Success at Late Follow Up (LFU) in the microITT Population

    Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

    Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)

  8. Microbiological Success at Late Follow Up (LFU) in the microITT Population

    Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.

    Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)

  9. Clinical Success at Late Follow Up (LFU) in the microITT Population

    Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

    Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)

  10. Investigator Opinion of Clinical Success at Test of Cure (TOC) in the microITT Population

    The proportion of patients with clinical success based on investigator opinion at TOC.

    Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)

  11. Composite Success in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the microITT Population

    Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

    Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)

  12. Microbiologic Success in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the microITT Population

    Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.

    Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)

  13. Clinical Success in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the microITT Population

    Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

    Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)

  14. Composite Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the microITT Population

    Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

    Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)

  15. Microbiologic Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the microITT Population

    Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.

    Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)

  16. Clinical Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the microITT Population

    Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

    Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)

  17. Composite Success in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the microITT Population

    Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

    Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)

  18. Microbiologic Success in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the microITT Population

    Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.

    Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)

  19. Clinical Success in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the microITT Population

    Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

    Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)

  20. Composite Success at End of Treatment (EOT) in the Microbiologically-Evaluable (ME) Population

    Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

    Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)

  21. Microbiologic Success at End of Treatment (EOT) in the ME Population

    Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.

    Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)

  22. Composite Success at Test of Cure (TOC) in the ME Population

    Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

    Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)

  23. Microbiologic Success at Test of Cure (TOC) in the ME Population

    Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.

    Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)

  24. Composite Success at Late Follow Up (LFU) in the ME Population

    Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

    Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)

  25. Microbiologic Success at Late Follow Up (LFU) in the ME Population

    Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.

    Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)

  26. Composite Success in Patients With Cefepime-Resistant Pathogens at the End of Treatment (EOT) in the ME Population

    Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

    Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)

  27. Microbiologic Success in Patients With Cefepime-Resistant Pathogens at the End of Treatment (EOT) in the ME Population

    Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.

    Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)

  28. Composite Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the ME Population

    Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

    Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)

  29. Microbiologic Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the ME Population

    Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.

    Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)

  30. Composite Success in Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the ME Population

    Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

    Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)

  31. Microbiologic Success in Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the ME Population

    Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.

    Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)

  32. Clinical Success at End of Treatment (EOT) in the Clinically Evaluable (CE) Population

    Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

    Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)

  33. Clinical Success at Test of Cure (TOC) in the CE Population

    Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

    Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)

  34. Clinical Success at Late Follow Up (LFU) in the CE Population

    Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

    Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)

  35. Clinical Success in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the CE Population

    Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

    Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)

  36. Clinical Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the CE Population

    Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

    Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)

  37. Clinical Success in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the CE Population

    Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

    Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)

  38. Per-Pathogen Microbiologic Eradication at End of Treatment (EOT) in the microITT Population

    Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.

    Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)

  39. Per-Pathogen Microbiologic Eradication at Test of Cure (TOC) in the microITT Population

    Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.

    Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)

  40. Per-Pathogen Microbiologic Eradication at Late Follow Up (LFU) in the microITT Population

    Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.

    Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)

  41. Per-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the microITT Population

    Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.

    Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)

  42. Per-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the microITT Population

    Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.

    Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)

  43. Per-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the microITT Population

    Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.

    Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)

  44. Per-Pathogen Microbiologic Eradication at End of Treatment (EOT) in the ME Population

    Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.

    Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)

  45. Per-Pathogen Microbiologic Eradication at Test of Cure (TOC) in the ME Population

    Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.

    Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)

  46. Per-Pathogen Microbiologic Eradication at Late Follow Up (LFU) in the ME Population

    Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.

    Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)

  47. Per-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the ME Population

    Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.

    Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)

  48. Per-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at Test of Cure TOC in the ME Population

    Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.

    Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)

  49. Per-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the ME Population

    Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.

    Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)

Other outcomes

  1. Number of Patients With Treatment-Emergent Adverse Events

    Percent of participants experiencing Treatment Emergent Adverse Events (TEAE). Treatment emergent is defined as any event that starts or worsens during or after treatment.

    Time frame: Study Days 1 to 35

  2. Number of Patients With Serious Adverse Events

    Percent of participants experiencing treatment emergent Serious Adverse Events (SAE).

    Time frame: Study Days 1 to 35

07

Results

Posted May 29, 2024

Participant flow

Six-hundred sixty-one (661) male and female patients with complicated urinary tract infection (cUTI) including acute pyelonephritis (AP), were randomized into 2 groups (cefepime - VNRX-5133, and meropenem) at 68 hospital sites in North and South America, Eastern Europe, and China, from August 2019 until the last patient's final visit in December 2021. Of these 661 patients in the intent-to-treat (ITT) population, 436 were in the MicroITT population (293 cefepime - VNRX-5133, 143 meropenem).

Study Drug Disposition
Participant flow — Study Drug Disposition
MilestoneCefepime/VNRX-5133 (Taniborbactam)Meropenem
Started441220
Completed414212
Not completed278
Withdrew: Adverse event132
Withdrew: Withdrawal by subject82
Withdrew: Lack of efficacy30
Withdrew: Physician decision20
Withdrew: Randomized but not treated, iwrs issue, lack of imp supplies.14
Study Completion Disposition
Participant flow — Study Completion Disposition
MilestoneCefepime/VNRX-5133 (Taniborbactam)Meropenem
Started441220
Completed426214
Not completed156
Withdrew: Withdrawal by subject62
Withdrew: Physician decision20
Withdrew: Covid-19 related20
Withdrew: Lost to follow-up11
Withdrew: Death10
Withdrew: Iwrs issue, patient refused, sae, randomized in error, patient did not take imp or attend visits.33

Outcome measures

PrimaryComposite Success at Test of Cure (TOC) in the Microbiological Intent-to-treat (microITT) Population

Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

Time frame:
Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Reported as:
Count of participants · Participants
Composite Success at Test of Cure (TOC) in the Microbiological Intent-to-treat (microITT) Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Composite Success at Test of Cure (TOC) in the Microbiological Intent-to-treat (microITT) Population20783
Statistical analysis
  • Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem · Cochran-Mantel-Haenszel · p = 0.0088 (P-value for superiority since the lower confidence interval is greater than 0 for the primary endpoint analysis.) · Miettinen and nurminen: 12.6 · 95% CI 3.1 to 22.2
SecondaryMicrobiologic Success at Test of Cure (TOC) in the microITT Population

Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.

Time frame:
Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Reported as:
Count of participants · Participants
Microbiologic Success at Test of Cure (TOC) in the microITT Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Microbiologic Success at Test of Cure (TOC) in the microITT Population22995
Statistical analysis
  • Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem · Miettinen and nurminen: 11.7 · 95% CI 2.9 to 21.0
SecondaryClinical Success at Test of Cure (TOC) in the microITT Population

Symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

Time frame:
Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Reported as:
Count of participants · Participants
Clinical Success at Test of Cure (TOC) in the microITT Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Clinical Success at Test of Cure (TOC) in the microITT Population251116
Statistical analysis
  • Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem · Miettinen and nurminen: 4.5 · 95% CI -2.6 to 12.6
SecondaryComposite Success at Test of Cure (TOC) in the Extended Microbiological Intent-to-treat (emicroITT) Population

Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

Time frame:
Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Reported as:
Count of participants · Participants
Composite Success at Test of Cure (TOC) in the Extended Microbiological Intent-to-treat (emicroITT) Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Composite Success at Test of Cure (TOC) in the Extended Microbiological Intent-to-treat (emicroITT) Population21686
Statistical analysis
  • Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem · Miettinen and nurminen: 12.3 · 95% CI 3.0 to 21.8
SecondaryComposite Success at End of Treatment (EOT) in the microITT Population

Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

Time frame:
Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Reported as:
Count of participants · Participants
Composite Success at End of Treatment (EOT) in the microITT Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Composite Success at End of Treatment (EOT) in the microITT Population261123
Statistical analysis
  • Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem · Miettinen and nurminen: 3.1 · 95% CI -3.2 to 10.4
SecondaryMicrobiological Success at End of Treatment (EOT) in the microITT Population

Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.

Time frame:
Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Reported as:
Count of participants · Participants
Microbiological Success at End of Treatment (EOT) in the microITT Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Microbiological Success at End of Treatment (EOT) in the microITT Population284139
Statistical analysis
  • Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem · Miettinen and nurminen: -0.3 · 95% CI -3.5 to 4.1
SecondaryClinical Success at End of Treatment (EOT) in the microITT Population

Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

Time frame:
Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Reported as:
Count of participants · Participants
Clinical Success at End of Treatment (EOT) in the microITT Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Clinical Success at End of Treatment (EOT) in the microITT Population265127
Statistical analysis
  • Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem · Miettinen and nurminen: 1.6 · 95% CI -4.1 to 8.5
SecondaryComposite Success at Late Follow Up (LFU) in the microITT Population

Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

Time frame:
Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Reported as:
Count of participants · Participants
Composite Success at Late Follow Up (LFU) in the microITT Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Composite Success at Late Follow Up (LFU) in the microITT Population18774
Statistical analysis
  • Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem · Miettinen and nurminen: 12.1 · 95% CI 2.2 to 21.9
SecondaryMicrobiological Success at Late Follow Up (LFU) in the microITT Population

Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.

Time frame:
Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Reported as:
Count of participants · Participants
Microbiological Success at Late Follow Up (LFU) in the microITT Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Microbiological Success at Late Follow Up (LFU) in the microITT Population20790
Statistical analysis
  • Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem · Miettinen and nurminen: 7.7 · 95% CI -1.6 to 17.3
SecondaryClinical Success at Late Follow Up (LFU) in the microITT Population

Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

Time frame:
Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Reported as:
Count of participants · Participants
Clinical Success at Late Follow Up (LFU) in the microITT Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Clinical Success at Late Follow Up (LFU) in the microITT Population238102
Statistical analysis
  • Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem · Miettinen and nurminen: 9.9 · 95% CI 1.5 to 18.8
SecondaryInvestigator Opinion of Clinical Success at Test of Cure (TOC) in the microITT Population

The proportion of patients with clinical success based on investigator opinion at TOC.

Time frame:
Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Reported as:
Count of participants · Participants
Investigator Opinion of Clinical Success at Test of Cure (TOC) in the microITT Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Investigator Opinion of Clinical Success at Test of Cure (TOC) in the microITT Population271128
Statistical analysis
  • Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem · Miettinen and nurminen: 3.0 · 95% CI -2.4 to 9.6
SecondaryComposite Success in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the microITT Population

Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

Time frame:
Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Reported as:
Count of participants · Participants
Composite Success in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the microITT Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Cefepime-resistant Enterobacterales5726
Cefepime-resistant Pseudomonas aeruginosa1—
SecondaryMicrobiologic Success in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the microITT Population

Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.

Time frame:
Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Reported as:
Count of participants · Participants
Microbiologic Success in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the microITT Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Cefepime-resistant Enterobacterales6528
Cefepime-resistant Pseudomonas aeruginosa1—
SecondaryClinical Success in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the microITT Population

Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

Time frame:
Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Reported as:
Count of participants · Participants
Clinical Success in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the microITT Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Enterobacterales5728
Pseudomonas aeruginosa1—
SecondaryComposite Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the microITT Population

Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

Time frame:
Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Reported as:
Count of participants · Participants
Composite Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the microITT Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Cefepime-resistant Enterobacterales4716
Cefepime-resistant Pseudomonas aeruginosa0—
SecondaryMicrobiologic Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the microITT Population

Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.

Time frame:
Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Reported as:
Count of participants · Participants
Microbiologic Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the microITT Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Cefepime-resistant Enterobacterales5018
Cefepime-resistant Pseudomonas aeruginosa0—
SecondaryClinical Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the microITT Population

Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

Time frame:
Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Reported as:
Count of participants · Participants
Clinical Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the microITT Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Enterbacterales5425
Pseudomonas aeruginosa0—
SecondaryComposite Success in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the microITT Population

Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

Time frame:
Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Reported as:
Count of participants · Participants
Composite Success in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the microITT Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Cefepime-resistant Enterobacterales4513
Cefepime-resistant Pseudomonas aeruginosa0—
SecondaryMicrobiologic Success in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the microITT Population

Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.

Time frame:
Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Reported as:
Count of participants · Participants
Microbiologic Success in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the microITT Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Cefepime-resistant Enterobacterales4816
Cefepime-resistant Pseudomonas aeruginosa0—
SecondaryClinical Success in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the microITT Population

Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

Time frame:
Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Reported as:
Count of participants · Participants
Clinical Success in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the microITT Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Enterobacterales4920
Pseudomonas aeruginosa0—
SecondaryComposite Success at End of Treatment (EOT) in the Microbiologically-Evaluable (ME) Population

Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

Time frame:
Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Reported as:
Count of participants · Participants
Composite Success at End of Treatment (EOT) in the Microbiologically-Evaluable (ME) Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Composite Success at End of Treatment (EOT) in the Microbiologically-Evaluable (ME) Population259121
Statistical analysis
  • Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem · Miettinen and nurminen: 3.5 · 95% CI -2.3 to 10.5
SecondaryMicrobiologic Success at End of Treatment (EOT) in the ME Population

Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.

Time frame:
Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Reported as:
Count of participants · Participants
Microbiologic Success at End of Treatment (EOT) in the ME Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Microbiologic Success at End of Treatment (EOT) in the ME Population279137
Statistical analysis
  • Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem · Miettinen and nurminen: -1.1 · 95% CI -3.1 to 1.7
SecondaryComposite Success at Test of Cure (TOC) in the ME Population

Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

Time frame:
Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Reported as:
Count of participants · Participants
Composite Success at Test of Cure (TOC) in the ME Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Composite Success at Test of Cure (TOC) in the ME Population19576
Statistical analysis
  • Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem · Miettinen and nurminen: 14.9 · 95% CI 5.0 to 24.9
SecondaryMicrobiologic Success at Test of Cure (TOC) in the ME Population

Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.

Time frame:
Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Reported as:
Count of participants · Participants
Microbiologic Success at Test of Cure (TOC) in the ME Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Microbiologic Success at Test of Cure (TOC) in the ME Population21488
Statistical analysis
  • Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem · Miettinen and nurminen: 12.7 · 95% CI 3.7 to 22.3
SecondaryComposite Success at Late Follow Up (LFU) in the ME Population

Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

Time frame:
Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Reported as:
Count of participants · Participants
Composite Success at Late Follow Up (LFU) in the ME Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Composite Success at Late Follow Up (LFU) in the ME Population17869
Statistical analysis
  • Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem · Miettinen and nurminen: 14.0 · 95% CI 3.8 to 24.3
SecondaryMicrobiologic Success at Late Follow Up (LFU) in the ME Population

Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.

Time frame:
Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Reported as:
Count of participants · Participants
Microbiologic Success at Late Follow Up (LFU) in the ME Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Microbiologic Success at Late Follow Up (LFU) in the ME Population19284
Statistical analysis
  • Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem · Miettinen and nurminen: 7.7 · 95% CI -1.9 to 17.7
SecondaryComposite Success in Patients With Cefepime-Resistant Pathogens at the End of Treatment (EOT) in the ME Population

Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

Time frame:
Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Reported as:
Count of participants · Participants
Composite Success in Patients With Cefepime-Resistant Pathogens at the End of Treatment (EOT) in the ME Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Cefepime-resistant Enterobacterales5626
Cefepime-resistant Pseudomonas aeruginosa1—
SecondaryMicrobiologic Success in Patients With Cefepime-Resistant Pathogens at the End of Treatment (EOT) in the ME Population

Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.

Time frame:
Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Reported as:
Count of participants · Participants
Microbiologic Success in Patients With Cefepime-Resistant Pathogens at the End of Treatment (EOT) in the ME Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Cefepime-resistant Enterobacterales6228
Cefepime-resistant Pseudomonas aeruginosa1—
SecondaryComposite Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the ME Population

Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

Time frame:
Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Reported as:
Count of participants · Participants
Composite Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the ME Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Cefepime-resistant Enterobacterales4412
Cefepime-resistant Pseudomonas aeruginosa0—
SecondaryMicrobiologic Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the ME Population

Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.

Time frame:
Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Reported as:
Count of participants · Participants
Microbiologic Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the ME Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Cefepime-resistant Enterobacterales4614
Cefepime-resistant Pseudomonas aeruginosa0—
SecondaryComposite Success in Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the ME Population

Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

Time frame:
Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Reported as:
Count of participants · Participants
Composite Success in Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the ME Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Cefepime-resistant Enterobacterales4411
Cefepime-resistant Pseudomonas aeruginosa0—
Statistical analysis
  • Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem · Miettinen and nurminen: 14.0 · 95% CI 3.8 to 24.3
SecondaryMicrobiologic Success in Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the ME Population

Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.

Time frame:
Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Reported as:
Count of participants · Participants
Microbiologic Success in Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the ME Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Cefepime-resistant Enterobacterales4514
Cefepime-resistant Pseudomonas aeruginosa0—
SecondaryClinical Success at End of Treatment (EOT) in the Clinically Evaluable (CE) Population

Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

Time frame:
Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Reported as:
Count of participants · Participants
Clinical Success at End of Treatment (EOT) in the Clinically Evaluable (CE) Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Clinical Success at End of Treatment (EOT) in the Clinically Evaluable (CE) Population384187
Statistical analysis
  • Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem · Miettinen and nurminen: 1.7 · 95% CI -3.1 to 7.3
SecondaryClinical Success at Test of Cure (TOC) in the CE Population

Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

Time frame:
Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Reported as:
Count of participants · Participants
Clinical Success at Test of Cure (TOC) in the CE Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Clinical Success at Test of Cure (TOC) in the CE Population343162
Statistical analysis
  • Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem · Miettinen and nurminen: 4.8 · 95% CI -1.1 to 11.5
SecondaryClinical Success at Late Follow Up (LFU) in the CE Population

Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

Time frame:
Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Reported as:
Count of participants · Participants
Clinical Success at Late Follow Up (LFU) in the CE Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Clinical Success at Late Follow Up (LFU) in the CE Population321142
Statistical analysis
  • Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem · Miettinen and nurminen: 8.2 · 95% CI 1.2 to 15.7
SecondaryClinical Success in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the CE Population

Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

Time frame:
Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Reported as:
Count of participants · Participants
Clinical Success in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the CE Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Enterobacterales6331
Pseudomonas aeruginosa62
SecondaryClinical Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the CE Population

Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

Time frame:
Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Reported as:
Count of participants · Participants
Clinical Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the CE Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Enterobacterales5623
Pseudomonas aeruginosa42
SecondaryClinical Success in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the CE Population

Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.

Time frame:
Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Reported as:
Count of participants · Participants
Clinical Success in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the CE Population
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Enterobacterales5219
Pseudomonas aeruginosa31
SecondaryPer-Pathogen Microbiologic Eradication at End of Treatment (EOT) in the microITT Population

Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.

Time frame:
Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Reported as:
Count of units · pathogens
Per-Pathogen Microbiologic Eradication at End of Treatment (EOT) in the microITT Population
pathogensCefepime/VNRX-5133 (Taniborbactam)Meropenem
Citrobacter freundii complex22
Citrobacter koseri11
Enterobacter cloacae complex143
Escherichia coli19795
Klebsiella aerogenes11
Klebsiella oxytoca51
Klebsiella pneumoniae3720
Klebsiella variicola11
Kluyvera ascorbata1—
Morganella morganii22
Proteus hauseri1—
Proteus mirabilis1010
Proteus penneri1—
Proteus vulgaris2—
Serratia marcescens2—
Providencia rettgeri—1
Pseudomonas aeruginosa116
SecondaryPer-Pathogen Microbiologic Eradication at Test of Cure (TOC) in the microITT Population

Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.

Time frame:
Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Reported as:
Count of units · pathogens
Per-Pathogen Microbiologic Eradication at Test of Cure (TOC) in the microITT Population
pathogensCefepime/VNRX-5133 (Taniborbactam)Meropenem
Citrobacter freundii complex22
Citrobacter koseri01
Enterobacter cloacae complex121
Escherichia coli16567
Klebsiella aerogenes00
Klebsiella oxytoca51
Klebsiella pneumoniae2714
Klebsiella varricola11
Kluyvera ascorbata1—
Morganella morganii22
Proteus hauseri0—
Proteus mirabilis95
Proteus penneri1—
Proteus vulgaris1—
Providencia rettgeri—1
Serratia marcescens2—
Pseudomonas aeruginosa54
SecondaryPer-Pathogen Microbiologic Eradication at Late Follow Up (LFU) in the microITT Population

Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.

Time frame:
Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Reported as:
Count of units · pathogens
Per-Pathogen Microbiologic Eradication at Late Follow Up (LFU) in the microITT Population
pathogensCefepime/VNRX-5133 (Taniborbactam)Meropenem
Citrobacter freundii complex12
Citrobacter koseri01
Enterobacter cloacae complex121
Escherichia coli14161
Klebsiella aerogenes00
Klebsiella oxytoca41
Klebsiella pneumoniae3014
Klebsiella variicola11
Kluyvera ascorbata1—
Morganella morganii22
Proteus hauseri0—
Proteus mirabilis86
Proteus penneri1—
Proteus vulgaris2—
Providencia rettgeri—1
Serratia marcescens2—
Pseudomonas aeruginosa54
SecondaryPer-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the microITT Population

Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.

Time frame:
Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Reported as:
Number · percentage of pathogen eradication
Per-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the microITT Population
percentage of pathogen eradicationCefepime/VNRX-5133 (Taniborbactam)Meropenem
Enterobacter cloacae complex100100
Escherichia coli10088.9
Klebsiella oxytoca100—
Klebsiella pneumoniae95.0100
Morganella morganii—100
Proteus mirabilis100100
Pseudomonas aeruginosa100—
SecondaryPer-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the microITT Population

Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.

Time frame:
Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Reported as:
Number · percentage of eradicated pathogens
Per-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the microITT Population
percentage of eradicated pathogensCefepime/VNRX-5133 (Taniborbactam)Meropenem
Enterobacter cloacae complex10050.0
Escherichia coli81.161.1
Klebsiella oxytoca100—
Klebsiella pneumoniae60.071.4
Morganella morganii—100
Proteus mirabilis50.00
Pseudomonas aeruginosa0—
SecondaryPer-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the microITT Population

Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.

Time frame:
Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Reported as:
Number · percentage of pathogen eradication
Per-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the microITT Population
percentage of pathogen eradicationCefepime/VNRX-5133 (Taniborbactam)Meropenem
Enterobacter cloacae complex10050.0
Escherichia coli73.050.0
Klebsiella oxytoca100—
Klebsiella pneumoniae65.071.4
Morganella morganii—100
Proteus mirabilis50.00
Pseudomonas aeruginosa0—
SecondaryPer-Pathogen Microbiologic Eradication at End of Treatment (EOT) in the ME Population

Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.

Time frame:
Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Reported as:
Count of units · pathogens
Per-Pathogen Microbiologic Eradication at End of Treatment (EOT) in the ME Population
pathogensCefepime/VNRX-5133 (Taniborbactam)Meropenem
Citrobacter freundii complex22
Citrobacter koseri11
Enterobacter cloacae complex143
Escherichia coli19394
Klebsiella aerogenes11
Klebsiella oxytoca51
Klebsiella pneumoniae3720
Klebsiella variicola11
Kluyvera ascorbata1—
Morganella morganii22
Proteus hauseri1—
Proteus mirabilis99
Proteus penneri1—
Proteus vulgaris2—
Providencia rettgeri—1
Serratia marcescens2—
Pseudomonas aeruginosa116
SecondaryPer-Pathogen Microbiologic Eradication at Test of Cure (TOC) in the ME Population

Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.

Time frame:
Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Reported as:
Count of units · pathogens
Per-Pathogen Microbiologic Eradication at Test of Cure (TOC) in the ME Population
pathogensCefepime/VNRX-5133 (Taniborbactam)Meropenem
Citrobacter freundii complex22
Citrobacter koseri01
Enterobacter cloacae complex110
Escherichia coli15464
Klebsiella aerogenes00
Klebsiella oxytoca51
Klebsiella pneumoniae2612
Klebsiella variicola11
Kluyvera ascorbata1—
Morganella morganii21
Proteus hauseri0—
Proteus mirabilis85
Proteus penneri1—
Proteus vulgaris1—
Providencia rettgeri—1
Serratia marcescens1—
Pseudomonas aeruginosa54
SecondaryPer-Pathogen Microbiologic Eradication at Late Follow Up (LFU) in the ME Population

Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.

Time frame:
Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Reported as:
Count of units · pathogens
Per-Pathogen Microbiologic Eradication at Late Follow Up (LFU) in the ME Population
pathogensCefepime/VNRX-5133 (Taniborbactam)Meropenem
Citrobacter freundii complex12
Citrobacter koseri—1
Enterobacter cloacae complex121
Escherichia coli13056
Klebsiella aerogenes00
Klebsiella oxytoca31
Klebsiella pneumoniae2914
Klebsiella variicola11
Kluyvera ascorbata1—
Morganella morganii21
Proteus hauseri0—
Proteus mirabilis66
Proteus penneri1—
Proteus vulgaris2—
Providencia rettgeri—1
Serratia marcescens2—
Pseudomonas aeruginosa54
SecondaryPer-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the ME Population

Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.

Time frame:
Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Reported as:
Number · percentage of pathogen eradication
Per-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the ME Population
percentage of pathogen eradicationCefepime/VNRX-5133 (Taniborbactam)Meropenem
Enterobacter cloacae complex100100
Escherichia coli100100
Klebsiella oxytoca100—
Klebsiella pneumoniae95.0100
Morganella morganii—100
Proteus mirabilis100100
Pseudomonas aeruginosa100—
SecondaryPer-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at Test of Cure TOC in the ME Population

Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.

Time frame:
Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Reported as:
Number · percentage of pathogen eradication
Per-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at Test of Cure TOC in the ME Population
percentage of pathogen eradicationCefepime/VNRX-5133 (Taniborbactam)Meropenem
Enterobacter cloacae complex1000
Escherichia coli87.566.7
Klebsiella oxytoca100—
Klebsiella pneumoniae64.766.7
Proteus mirabilis50.00
Pseudomonas aeruginosa0—
SecondaryPer-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the ME Population

Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.

Time frame:
Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Reported as:
Number · percentage of pathogen eradication
Per-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the ME Population
percentage of pathogen eradicationCefepime/VNRX-5133 (Taniborbactam)Meropenem
Enterobacter cloacae complex10050.0
Escherichia coli78.153.3
Klebsiella pneumoniae68.471.4
Proteus mirabilis50.00
Pseudomonas aeruginosa0—
Other pre-specifiedNumber of Patients With Treatment-Emergent Adverse Events

Percent of participants experiencing Treatment Emergent Adverse Events (TEAE). Treatment emergent is defined as any event that starts or worsens during or after treatment.

Time frame:
Study Days 1 to 35
Reported as:
Count of participants · Participants
Number of Patients With Treatment-Emergent Adverse Events
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Number of Patients With Treatment-Emergent Adverse Events15663
Other pre-specifiedNumber of Patients With Serious Adverse Events

Percent of participants experiencing treatment emergent Serious Adverse Events (SAE).

Time frame:
Study Days 1 to 35
Reported as:
Count of participants · Participants
Number of Patients With Serious Adverse Events
ParticipantsCefepime/VNRX-5133 (Taniborbactam)Meropenem
Number of Patients With Serious Adverse Events94

Adverse events

Collected over From first dose to last follow-up visit (Day 28-35).. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cefepime/VNRX-5133 (Taniborbactam)1/440 (0.2%)9/440 (2%)93/440 (21.1%)
Meropenem0/217 (0%)4/217 (1.8%)37/217 (17.1%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventCefepime/VNRX-5133 (Taniborbactam)Meropenem
PyelonephritisInfections and infestations0/4402/217
Pyelonephritis acuteInfections and infestations0/4401/217
Tubo-ovarian abscessInfections and infestations0/4401/217
UreterolithiasisRenal and urinary disorders0/4401/217
COVID-19Infections and infestations2/4400/217
AppendicitisInfections and infestations1/4400/217
EndocarditisInfections and infestations1/4400/217
Gastrointestinal candidiasisInfections and infestations1/4400/217
Renal abscessInfections and infestations1/4400/217
Urinary tract infectionInfections and infestations1/4400/217
Most frequent other events
Showing 10 of 14
Most frequent other events
EventCefepime/VNRX-5133 (Taniborbactam)Meropenem
HeadacheNervous system disorders27/4408/217
DiarrhoeaGastrointestinal disorders18/4405/217
ConstipationGastrointestinal disorders14/4403/217
Alanine aminotransferase increasedInvestigations4/4405/217
HypertensionVascular disorders9/4402/217
NauseaGastrointestinal disorders9/4402/217
Abdominal distensionGastrointestinal disorders7/4403/217
DizzinessNervous system disorders7/4401/217
HypokalaemiaMetabolism and nutrition disorders7/4401/217
AnaemiaBlood and lymphatic system disorders6/4403/217

Baseline characteristics

Intent-to-treat (ITT) population: all randomized patients

Age, Continuous
Age, Continuous(years)Cefepime/VNRX-5133 (Taniborbactam)MeropenemTotal
Mean56.2 ± 17.4355.8 ± 18.1556.1 ± 17.66
Age, Customized
Age, Customized(Participants)Cefepime/VNRX-5133 (Taniborbactam)MeropenemTotal
Age Categories (years) — <65275137412
Age Categories (years) — 65 - 7511156167
Age Categories (years) — >75552782
Sex: Female, Male
Sex: Female, Male(Participants)Cefepime/VNRX-5133 (Taniborbactam)MeropenemTotal
Female248115363
Male193105298
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cefepime/VNRX-5133 (Taniborbactam)MeropenemTotal
Hispanic or Latino472067
Not Hispanic or Latino393199592
Unknown or Not Reported112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cefepime/VNRX-5133 (Taniborbactam)MeropenemTotal
American Indian or Alaska Native415
Asian361753
Native Hawaiian or Other Pacific Islander000
Black or African American336
White386191577
More than one race000
Unknown or Not Reported12820
08

Study locations

78 sites
  • Site 184003
    Buena Park, California 90620, United States
  • Site 184002
    Chula Vista, California 91911, United States
  • Site 184001
    La Mesa, California 91942, United States
  • 184012
    Northridge, California 91324, United States
  • Site 103203
    Córdoba, X5016KEH, Argentina
  • Site 107601
    Belo Horizonte, 30150-221, Brazil
  • Site 107608
    San Paolo, 04039-901, Brazil
  • Site 110009
    Gabrovo, 5300, Bulgaria
  • Site 110002
    Pleven, 5800, Bulgaria
  • Site 110007
    Plovdiv, 4003, Bulgaria
  • Site 110003
    Ruse, 7002, Bulgaria
  • Site 110010
    Sofia, 1407, Bulgaria
  • Site 110004
    Sofia, 1606, Bulgaria
  • Site 110005
    Sofia, 1606, Bulgaria
  • Site 110008
    Sofia, 1606, Bulgaria
  • Site 110001
    Veliko Tarnovo, 5000, Bulgaria
  • Site 156022
    Baotou, 014010, China
  • Site 156002
    Beijing, 100034, China
  • Site 156006
    Beijing, 100050, China
  • Site 156015
    Chendu, 610041, China
  • Site 156011
    Chongqing, 400016, China
  • Site 156012
    Chongqing, 400038, China
  • Site 156004
    Dalian, 116023, China
  • Site 156030
    Fujian, 362202, China
  • Site 156014
    Guangdong, 515041, China
  • Site 156027
    Guangdong, 518035, China
  • Site 156025
    Guangzhou, 510120, China
  • Site 156018
    Guiyang, 550002, China
  • Site 156003
    Nanchang, 330006, China
  • Site 156005
    Nanjing, 156005, China
  • Site 156008
    Nanjing, 210008, China
  • Site 156007
    Nanjing, 210009, China
  • Site 156013
    Ningbo, 315010, China
  • Site 156028
    Shandong, 276000, China
  • Site 156017
    Shanghai, 200025, China
  • Site 156016
    Shijiazhuang, 050000, China
  • Site 156020
    Tianjin, 300192, China
  • Site 156010
    Xiamen, 361003, China
  • Site 156029
    Ürümqi, 830054, China
  • Site 119103
    Split, 21000, Croatia
  • Site 119101
    Zagreb, 10000, Croatia
  • Site 119106
    Zagreb, 10000, Croatia
  • Site 134801
    Budapest, 1204, Hungary
  • Site 134803
    Nyiregyhaza, 4400, Hungary
  • Site 134804
    Szeged, 6725, Hungary
  • Site 142803
    Daugavpils, LV-5417, Latvia
  • Site 142804
    Riga, LV-1002, Latvia
  • Site 142801
    Riga, LV-1038, Latvia
  • Site 148402
    Colima, 28018, Mexico
  • Site 148401
    Guadalajara, 44280, Mexico
  • Site 160403
    Cuzco, 84, Peru
  • Site 160410
    Lima, 29, Peru
  • Site 160406
    Lima, 41, Peru
  • Site 160404
    Trujillo, TRUJ 01, Peru
  • Site 164204
    Bucharest, 050653, Romania
  • Site 164206
    Bucuresti, 010825, Romania
  • Site 164205
    Bucuresti, 020125, Romania
  • Site 164201
    Craiova, 200642, Romania
  • Site 164307
    Moscow, 117593, Russian Federation
  • Site 164301
    Penza, 440026, Russian Federation
  • Site 164308
    Pyatigorsk, 357500, Russian Federation
  • Site 164311
    Rostov-on-Don, 344011, Russian Federation
  • Site 164303
    Sankt Peterburg, 194044, Russian Federation
  • Site 164302
    Saratov, 410054, Russian Federation
  • Site 189001
    Belgrade, 11000, Serbia
  • Site 189002
    Belgrade, 11080, Serbia
  • Site 179207
    Adapazarı, 54100, Turkey
  • Site 179203
    Bornova, 35040, Turkey
  • Site 179202
    Bostanci, 61080, Turkey
  • Site 179204
    Diyarbakır, 21280, Turkey
  • Site 179205
    Çankaya, 06800, Turkey
  • Site 180404
    Dnipro, 49005, Ukraine
  • Site 180408
    Ivano-Frankivs'k, 76014, Ukraine
  • Site 180402
    Kharkiv, 6111, Ukraine
  • Site 180406
    Kyiv, 02125, Ukraine
  • Site 180401
    Luts'k, 43000, Ukraine
  • Site 180403
    Vinnytsia, 21018, Ukraine
  • Site 180407
    Zaporizhzhya, 69600, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Dec 2021, 28 months.

Results were first posted in May 2024, 2 years 5 months after primary completion. A results delay was requested in Dec 2022.

Of 23 industry-sponsored phase 3 interventional studies under Urinary Tract Infections, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 28 months is above that.

Counting every sponsor, half of 37 studies reached it within 20 months; a quarter within 14 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2019
First posted
Feb 15, 2019
StartActual
Aug 7, 2019
Primary completionActual
Dec 14, 2021
CompletionActual
Dec 14, 2021
Results delay requested
Dec 8, 2022
Results first posted
May 29, 2024
Last update
Jun 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03840148
Lead sponsor
Venatorx Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Feb 15, 2019
Start date
Aug 7, 2019
Primary completion
Dec 14, 2021
Completion
Dec 14, 2021
Results posted
May 29, 2024
Last update
Jun 6, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Taniborbactam

Start the discussion